Sign up for ICER's Weekly View Newsletter

 

Weekly View


August 7, 2026

From the desk of Priya Ranade

Good morning, everyone.

Oveporexton was approved yesterday for treatment of narcolepsy type 1. ICER found that oveporexton (now branded Orzeyful) has at least a small, but likely substantial, net health benefit compared to no pharmacological treatment — resulting in an ICER evidence rating of B+.


ICER also stated that the treatment would meet common cost-effectiveness thresholds if priced between $50,400 and $59,400 per year. Takeda has not yet announced a price.


According to ICER's ICER’s Senior Vice President of Research, Foluso Agboola, MBBS, MPH:


“The narcolepsy treatment landscape includes several pricey medications that do not provide complete relief for patients. ICER’s analyses found that oveporexton, the first medication for narcolepsy type 1 that directly addresses the underlying cause of the condition, is effective in promoting wakefulness, improving quality of life, and appears to offer better health benefits than current options. The manufacturer choosing a value-based price for oveporexton would help de-escalate the cycle of high prices being met with onerous access challenges. Our independent analysis can offer a roadmap for improving affordability and access for patients and the health system.”

Let's see what else happened this week...

 

ICER in the News

 

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

MarketWatch

MarketWatch's Jaimy Lee and Steve Goldstein analyzed the impact of competition in the GLP-1 space. They interviewed ICER's President and CEO, Sarah K. Emond, MPP:


"Within seven months of Wegovy’s approval, Novo announced the medication was in short supply due to an external manufacturing issue. As the company worked on shoring up its manufacturing capacity, a cultural shift was under way that neither Novo nor Lilly predicted.


'There was unbelievable interest in these drugs, and you saw demand far outweigh the ability of these companies to produce the supply,' said Sarah Emond, chief executive of the Institute for Clinical and Economic Review... We’ve never seen anything like this in the pharmaceutical space.'”

EP523: The Sleeping Giants of Healthcare—Why Self-insured Employers and Clinicians Keep Missing Each Other, With Suhas Gondi, MD, MBA

Relentless Health Value (podcast) 

This week's Relentless Health podcast with Stacey Richter and Dr. Suhad Gondi examines the dynamic between self-insured employers and clinicians.

 

During their conversation, Stacey Richter references a past episode with ICER’s President and CEO, Sarah K. Emond, MPP, where they discuss how some innovative therapies, like GLP-1s, are cost effective and yet there are still significant barriers to access. To listen to Sarah's full episode on the "Six Tensions of Pharmaceutical Drug Pricing", click here.

 
Pharmaceutical News

MUST READS


The Economics Of Orphan Blockbuster Drug Development

Health Affairs

Researchers at Verdant Research recently analyzed the orphan drug exemptions and delays built into the in the Medicare Drug Price Negotiation Program. They stated:


“Orphan provisions of the Medicare Drug Price Negotiation Program prevent or delay negotiation for high-revenue drugs that recover costs at rates comparable to or faster than those of their nonqualifying peers. These protections reduce savings from that program while potentially distorting clinical development if manufacturers avoid pursuing nonorphan indications to preserve exemption status. Policy makers should weigh whether protections beyond those already provided by the Orphan Drug Act are necessary for drugs whose commercial success suggests that they would have been developed regardless.”

Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds

STAT

Excluding rare disease treatments from a Medicare pilot program to lower drug prices would wipe out much of the savings from retail drugs, according to a Harvard University researcher. 


Biotech companies are lobbying the Trump administration to exclude treatments for rare, or “orphan,” diseases from two Medicare pilot programs: Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD). Those pilots are part of President Trump’s plan to get drugmakers to lower prices in the United States to the levels seen in other rich countries, an approach generally referred to as a “most-favored nation” policy.


The exact scope of those pilot programs has been in question. Some companies that struck most-favored nation pricing deals with the White House — including many of the largest drugmakers globally — have said they were exempted from the pilots, though details of those deals have not been made public. 

Trump administration tries again to institute rebates in 340B

BioPharma Dive

The Trump administration is taking another shot at requiring rebates in the 340B drug discount program. Last Friday, the Health Resources and Services Administration said some discounts in 340B would be given in the form of rebates, instead of upfront savings, starting in 2027. It’s the second time the Trump administration has tried to impose rebates in the program, after another proposed pilot was scrapped earlier this year following losses in court.

Senate confirms Erica Schwartz as new CDC leader

The Hill

The Centers for Disease Control and Prevention (CDC) will soon have a new official director for the first time in nearly a year, after the Senate on Wednesday voted to confirm Dr. Erica Schwartz. 


Schwartz was confirmed on a mostly party-line 51-44 vote. Sen. Tim Kaine (Va.) was the lone Democrat to vote in her favor.  

OTHER HEADLINES

 
 

Key Upcoming Dates

 
  • 8/12: Hypertension — Draft Evidence Report
  • 9/16: Parkinson's Disease — Evidence Report
  • 10/1: Hypertension — Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email